Save your place

Sign in to WhoBought

Please try again later.

aTyr Pharma, Inc. (ATYR) institutional ownership

Latest close $0.49 Jul 20, 2026
Market cap$54M 52-week range SectorHealthcare
Funds holding · Q1 2026
97
reported ATYR position changes
Top owners · Q1 2026
No disclosed owners are available.
Institutional activity · Q1 2026
Net bought $1.0M
59 buyers · 38 sellers

aTyr Pharma, Inc. (ATYR) price and institutional activity

Dates

Q1 2026

$4.9M bought by 59 investors
UBS Group AG$1.9MMillennium Management LLC$1.4M +57 more
$3.9M sold by 38 investors
Rosalind Advisors, Inc.-$877KGsa Capital Partners LLP-$799K +36 more
Sign in to see who bought
Bought Sold Totals per quarter; hover a bar for the names.

aTyr Pharma, Inc. (ATYR) institutional activity · 97

Investor Type Est. change Change Δ Own Date
UBS Group AG · Added +$1.9M
Change +2.2M Date Q1 2026
UBS Group AG Added· Q1 2026 +$1.9M +2.2M Q1 2026
Millennium Management LLC · New +$1.4M
Change +1.6M Date Q1 2026
Millennium Management LLC New· Q1 2026 +$1.4M +1.6M Q1 2026
Rosalind Advisors, Inc. · Exited −$877K
Change −1.0M Δ Own −100.0% Date Q1 2026
Rosalind Advisors, Inc. Exited· Q1 2026 −$877K −1.0M −100.0% Q1 2026
Gsa Capital Partners LLP · Reduced −$799K
Change −946K Date Q1 2026
Gsa Capital Partners LLP Reduced· Q1 2026 −$799K −946K Q1 2026
Two Sigma Advisers, LP · Exited −$710K
Change −841K Δ Own −100.0% Date Q1 2026
Two Sigma Advisers, LP Exited· Q1 2026 −$710K −841K −100.0% Q1 2026
Two Sigma Investments, LP · Added +$583K
Change +690K Δ Own +151.9% Date Q1 2026
Two Sigma Investments, LP Added· Q1 2026 +$583K +690K +151.9% Q1 2026
Tikvah Management LLC · Exited −$389K
Change −461K Δ Own −100.0% Date Q1 2026
Tikvah Management LLC Exited· Q1 2026 −$389K −461K −100.0% Q1 2026
AQR Capital Management LLC · Reduced −$231K
Change −274K Date Q1 2026
AQR Capital Management LLC Reduced· Q1 2026 −$231K −274K Q1 2026
Morgan Stanley · Reduced −$150K
Change −178K Date Q1 2026
Morgan Stanley Reduced· Q1 2026 −$150K −178K Q1 2026
Bank of America Corp · Added +$149K
Change +177K Date Q1 2026
Bank of America Corp Added· Q1 2026 +$149K +177K Q1 2026
Jane Street Group, LLC · Reduced −$118K
Change −140K Date Q1 2026
Jane Street Group, LLC Reduced· Q1 2026 −$118K −140K Q1 2026
Marshall Wace, LLP · New +$117K
Change +138K Date Q1 2026
Marshall Wace, LLP New· Q1 2026 +$117K +138K Q1 2026
Barclays PLC · Reduced −$109K
Change −129K Date Q1 2026
Barclays PLC Reduced· Q1 2026 −$109K −129K Q1 2026
Vanguard · Added +$102K
Change +121K Date Q1 2026
Vanguard Added· Q1 2026 +$102K +121K Q1 2026
BlackRock · Reduced −$89K
Change −106K Date Q1 2026
BlackRock Reduced· Q1 2026 −$89K −106K Q1 2026
Data through Q1 2026 · filed May 21, 2026
15 of 97

Famous investor activity in aTyr Pharma, Inc. (ATYR)

aTyr Pharma, Inc. (ATYR) insider trading

Company insiders, action and economics first; trade and filed dates last.
Dates
Insider Title Type Price Qty Value Owned ΔOwn Trade date Filed date
Schimmel Paul · Director Buy +$50K
Price $0.50 Qty +100K Owned 779K Trade date May 27, 2026 Filed date May 28, 2026
Schimmel Paul Director Buy $0.50 +100K +$50K 779K May 27, 2026 May 28, 2026
Coughlin Timothy · Director Grant (A) 50K
Owned 50K Trade date May 11, 2026 Filed date May 13, 2026
Coughlin Timothy Director Grant (A) 50K 50K May 11, 2026 May 13, 2026
Benevich Eric · Director Grant (A) 50K
Owned 50K Trade date May 11, 2026 Filed date May 13, 2026
Benevich Eric Director Grant (A) 50K 50K May 11, 2026 May 13, 2026
Gross Jane A. · Director Grant (A) 50K
Owned 50K Trade date May 11, 2026 Filed date May 13, 2026
Gross Jane A. Director Grant (A) 50K 50K May 11, 2026 May 13, 2026
Lucas Svetlana · Director Grant (A) 50K
Owned 50K Trade date May 11, 2026 Filed date May 13, 2026
Lucas Svetlana Director Grant (A) 50K 50K May 11, 2026 May 13, 2026
Zaknoen Sara · Director Grant (A) 50K
Owned 50K Trade date May 11, 2026 Filed date May 13, 2026
Zaknoen Sara Director Grant (A) 50K 50K May 11, 2026 May 13, 2026
Schimmel Paul · Director Grant (A) 50K
Owned 50K Trade date May 11, 2026 Filed date May 13, 2026
Schimmel Paul Director Grant (A) 50K 50K May 11, 2026 May 13, 2026
Shukla Sanjay · Director, Officer Sell −$4K
Price $0.98 Qty −4K Owned 154K Trade date Feb 4, 2026 Filed date Feb 4, 2026
Shukla Sanjay Director, Officer Sell $0.98 −4K −$4K 154K Feb 4, 2026 Feb 4, 2026
Broadfoot Jill Marie · CFO Sell −$2K
Price $0.98 Qty −2K Owned 37K Trade date Feb 4, 2026 Filed date Feb 4, 2026
Broadfoot Jill Marie CFO Sell $0.98 −2K −$2K 37K Feb 4, 2026 Feb 4, 2026
Denyes Nancy · Officer Sell −$1K
Price $0.98 Qty −1K Owned 33K Trade date Feb 4, 2026 Filed date Feb 4, 2026
Denyes Nancy Officer Sell $0.98 −1K −$1K 33K Feb 4, 2026 Feb 4, 2026
Shukla Sanjay · Director, Officer 2 operations 0
Owned 0 Trade date Feb 3, 2026 Filed date Feb 4, 2026
Shukla Sanjay Director, Officer 2 operations 0 0 Feb 3, 2026 Feb 4, 2026
Broadfoot Jill Marie · CFO 2 operations 0
Owned 0 Trade date Feb 3, 2026 Filed date Feb 4, 2026
Broadfoot Jill Marie CFO 2 operations 0 0 Feb 3, 2026 Feb 4, 2026
Denyes Nancy · Officer 2 operations 0
Owned 0 Trade date Feb 3, 2026 Filed date Feb 4, 2026
Denyes Nancy Officer 2 operations 0 0 Feb 3, 2026 Feb 4, 2026
Shukla Sanjay · Director, Officer Grant (A) 1.5M
Owned 1.5M Trade date Jan 9, 2026 Filed date Jan 9, 2026
Shukla Sanjay Director, Officer Grant (A) 1.5M 1.5M Jan 9, 2026 Jan 9, 2026
Broadfoot Jill Marie · Officer Grant (A) 412K
Owned 412K Trade date Jan 9, 2026 Filed date Jan 9, 2026
Broadfoot Jill Marie Officer Grant (A) 412K 412K Jan 9, 2026 Jan 9, 2026
15 of 18
15 of 18 Sign in to continue to older insider transactions.

aTyr Pharma, Inc. (ATYR) activist and large shareholders

What are Schedules 13D and 13G?

Dates
Owner/Filer identity Shares reported % of shares outstanding Filing date
FMR LLC 8.8M
% of shares outstanding 15.0% Filing date Feb 9, 2024
FMR LLC 8.8M 15.0% Feb 9, 2024
Logos Global Management LP 5.8M
% of shares outstanding 9.9% Filing date Jan 2, 2024
Logos Global Management LP 5.8M 9.9% Jan 2, 2024
Federated Hermes, Inc. 8.5M
% of shares outstanding 8.7% Filing date Jul 8, 2026
Federated Hermes, Inc. 8.5M 8.7% Jul 8, 2026
Point72 Asset Management, L.P. 5.0M
% of shares outstanding 6.2% Filing date Oct 15, 2024
Point72 Asset Management, L.P. 5.0M 6.2% Oct 15, 2024
FMR LLC 5.9M
% of shares outstanding 6.1% Filing date Jun 5, 2026
FMR LLC 5.9M 6.1% Jun 5, 2026
Venrock Healthcare Capital Partners Ii, L.P. 1.2M
% of shares outstanding 4.0% Filing date Feb 14, 2023
Venrock Healthcare Capital Partners Ii, L.P. 1.2M 4.0% Feb 14, 2023
Tang Capital Partners LP 1.1M
% of shares outstanding 4.0% Filing date Feb 14, 2022
Tang Capital Partners LP 1.1M 4.0% Feb 14, 2022
Logos Global Management LP 1.8M
% of shares outstanding 2.1% Filing date Nov 14, 2024
Logos Global Management LP 1.8M 2.1% Nov 14, 2024
8 of 12

aTyr Pharma, Inc. (ATYR) ownership FAQ

Who owns ATYR?

97 reporting institutions disclosed ATYR position changes in the Q1 2026 snapshot.

How is institutional activity calculated?

For each manager, WhoBought compares accepted consecutive 13F share counts. Share change is current shares minus prior shares. Estimated dollar change is that signed share change multiplied by the split-adjusted quarter-mean close. The activity table on this page uses Q1 2026.

What are activist and large shareholder filings?

An investor crossing 5% of a share class generally files Schedule 13D for activist intent or Schedule 13G for a passive position. The technical form names appear here rather than in the activity rows.

Where does this data come from?

Ownership and institutional activity come from SEC Form 13F filings. Insider activity comes from SEC Form 4, and large-shareholder activity from SEC Schedules 13D and 13G. FMP supplies price data only. Company logos use the local verified Parqet cache with one shared fallback.

Why are ownership reports delayed?

Form 13F is a quarterly disclosure and is normally filed after the quarter ends. Every ownership and activity value therefore names its represented period; it is not presented as a live position.

How are missing table values shown?

A muted dash marks a missing table value. It means the filing omitted the value, comparable data is unavailable, or no prior position exists for comparison.